The Claim
In obese ZSF1 rats with heart failure with preserved ejection fraction, administration of semaglutide at a dose of 30 nmol/kg biweekly for 16 weeks reduces hepatic triglyceride and cholesterol levels and decreases lipid droplet accumulation, independent of changes in body weight.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese rats with a specific type of heart failure, a low dose of semaglutide given twice a week for 16 weeks lowers fat and cholesterol levels in the liver and reduces fat storage in liver cells, even when the rats do not lose weight.
See the scientific wording
In obese ZSF1 rats with heart failure with preserved ejection fraction, a low dose of semaglutide (30 nmol/kg biweekly for 16 weeks) reduces hepatic triglyceride and cholesterol levels and decreases lipid droplet accumulation, independent of body weight changes, suggesting a direct effect on liver lipid metabolism.
A signaling molecule binds to receptors on liver cells, turning off genes that store fat and turn on genes that burn fat and break down amino acids for energy. This shifts the liver from making and storing fat to using it up, reducing fat buildup without needing weight loss.
What the research says
1 studyIn obese rats with heart problems, a small dose of semaglutide cleaned up excess fat and cholesterol in the liver—even though the rats didn’t lose weight. This means the drug works directly on the liver, not just by making animals thinner.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.